---
title: 'Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA
  COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study'
date: '2023-12-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38085500/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231213170709&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Among people with COPD and asthma, the COVID-19 vaccines
  CoronaVac and BNT162b2 did not increase severe exacerbations and achieved moderate-to-high
  effectiveness against COVID-related outcomes. COVID-19 vaccination remains essential
  and should be encouraged to protect this vulnerable population in future epidemic
  ...'
disable_comments: true
---
CONCLUSIONS: Among people with COPD and asthma, the COVID-19 vaccines CoronaVac and BNT162b2 did not increase severe exacerbations and achieved moderate-to-high effectiveness against COVID-related outcomes. COVID-19 vaccination remains essential and should be encouraged to protect this vulnerable population in future epidemic ...